The identification of the ARAF p.S214C mutation as a potential biomarker for sorafenib responsiveness through the analysis of an exceptional responder case underscores the importance of comprehensive genetic profiling to guide and accelerate personalized cancer treatment strategies. Here, ARAF is linked to cancer.